Gamithromycin

• CAT Number: A001232
• CAS Number: 145435-72-9
• Molecular Formula: C40H76N2O12
• Molecular Weight: 777.00
• Purity: ≥95%
• Synonyms: (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopen
• Target: Bacterial
• Storage: 2-8°C
• IUPAC Name: (2R,3S,4R,5S,8R,10R,11R,12S,13S,14R)-11-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-7-propyl-1-oxa-7-azacyclopentadecan-15-one
• InChI: InChI=1S/C40H76N2O12/c1-15-17-42-21-22(3)33(44)40(11,48)29(16-2)52-36(46)26(7)32(53-30-20-39(10,49-14)34(45)27(8)51-30)25(6)35(38(9,47)19-23(42)4)54-37-31(43)28(41(12)13)18-24(5)50-37/h22-35,37,43-45,47-48H,15-21H2,1-14H3/t22-,23+,24+,25-,26+,27-,28-,29+,30-,31+,32-,33+,34-,35+,37-,38+,39+,40+/m0/s1
• InChIKey: VWAMTBXLZPEDQO-UZSBJOJWSA-N
• SMILES: CCCN1C[C@@H]([C@H]([C@]([C@H](OC(=O)[C@@H]([C@H]([C@@H]([C@H]([C@](C[C@H]1C)(C)O)O[C@H]2[C@@H]([C@H](C[C@H](O2)C)N(C)C)O)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)O)(C)OC)C)CC)(C)O)O)C

Gamithromycin（Cat No.:A001232）is a macrolide antibiotic primarily used in veterinary medicine to treat respiratory infections in cattle and swine, including bovine respiratory disease (BRD) caused by Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. It functions by binding to the 50S ribosomal subunit, inhibiting bacterial protein synthesis and leading to cell death. With its long-acting formulation, Gamithromycin provides sustained antibacterial activity, reducing the need for frequent dosing. In research, it aids in studying macrolide efficacy and resistance, offering valuable insights into improving animal health and optimizing antimicrobial therapies in livestock.

Reference

[1]: Kellermann M, Huang RA, Forbes AB, Rehbein S. Gamithromycin plasma and skin pharmacokinetics in sheep. Res Vet Sci. 2014 Oct;97(2):199-203. doi: 10.1016/j.rvsc.2014.08.008. Epub 2014 Sep 4. PubMed PMID: 25241389.
[2]: Wyns H, Meyer E, Plessers E, Watteyn A, De Baere S, De Backer P, Croubels S. Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs. Res Vet Sci. 2014 Feb;96(1):160-3. doi: 10.1016/j.rvsc.2013.11.012. Epub 2013 Dec 1. PubMed PMID: 24331716.
[3]: Mitchell JD, Goh S, McKellar QA, McKeever DJ. In vitro pharmacodynamics of gamithromycin against Mycoplasma mycoides subspecies mycoides Small Colony. Vet J. 2013 Sep;197(3):806-11. doi: 10.1016/j.tvjl.2013.05.025. Epub 2013 Jun 28. PubMed PMID: 23810743.
[4]: Berghaus LJ, Giguère S, Sturgill TL, Bade D, Malinski TJ, Huang R. Plasma pharmacokinetics, pulmonary distribution, and in vitro activity of gamithromycin in foals. J Vet Pharmacol Ther. 2012 Feb;35(1):59-66. doi: 10.1111/j.1365-2885.2011.01292.x. Epub 2011 Mar 28. PubMed PMID: 21443748.
[5]: Huang RA, Letendre LT, Banav N, Fischer J, Somerville B. Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity. J Vet Pharmacol Ther. 2010 Jun 1;33(3):227-37. doi: 10.1111/j.1365-2885.2009.01125.x. Erratum in: J Vet Pharmacol Ther. 2010 Dec;33(6):622. PubMed PMID: 20557439.